Alexander V Birk1, Wesley M Chao1, Shaoyi Liu1, Yi Soong1, Hazel H Szeto2. 1. Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10065, USA; Research Program in Mitochondrial Therapeutics, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10065, USA. 2. Department of Pharmacology, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10065, USA; Research Program in Mitochondrial Therapeutics, Joan and Sanford I. Weill Medical College of Cornell University, New York, NY 10065, USA. Electronic address: hhszeto@med.cornell.edu.
Abstract
BACKGROUND: It was recently suggested that electron flow into cyt c, coupled with ROS generation, oxidizes cyt c Met(80) to Met(80) sulfoxide (Met-O) in isolated hearts after ischemia-reperfusion, and converts cyt c to a peroxidase. We hypothesize that ischemia disrupts Met(80)-Fe ligation of cyt c, forming pentacoordinated heme Fe(2+), which inhibits electron transport (ET) and promotes oxygenase activity. METHODS: SS-20 (Phe-D-Arg-Phe-Lys-NH2) was used to demonstrate the role of Met(80)-Fe ligation in ischemia. Mitochondria were isolated from ischemic rat kidneys to determine sites of respiratory inhibition. Mitochondrial cyt c and cyt c Met-O were quantified by western blot, and cristae architecture was examined by electron microscopy. RESULTS: Biochemical and structural studies showed that SS-20 selectively targets cardiolipin (CL) and protects Met(80)-Fe ligation in cyt c. Ischemic mitochondria showed 17-fold increase in Met-O cyt c, and dramatic cristaeolysis. Loss of cyt c was associated with proteolytic degradation of OPA1. Ischemia significantly inhibited ET initiated by direct reduction of cyt c and coupled respiration. All changes were prevented by SS-20. CONCLUSION: Our results show that ischemia disrupts the Met(80)-Fe ligation of cyt c resulting in the formation of a globin-like pentacoordinated heme Fe(2+) that inhibits ET, and converts cyt c into an oxygenase to cause CL peroxidation and proteolytic degradation of OPA1, resulting in cyt c release. GENERAL SIGNIFICANCE: Cyt c heme structure represents a novel target for minimizing ischemic injury. SS-20, which we show to selectively target CL and protect the Met(80)-Fe ligation, minimizes ischemic injury and promotes ATP recovery.
BACKGROUND: It was recently suggested that electron flow into cyt c, coupled with ROS generation, oxidizes cyt c Met(80) to Met(80) sulfoxide (Met-O) in isolated hearts after ischemia-reperfusion, and converts cyt c to a peroxidase. We hypothesize that ischemia disrupts Met(80)-Fe ligation of cyt c, forming pentacoordinated hemeFe(2+), which inhibits electron transport (ET) and promotes oxygenase activity. METHODS:SS-20 (Phe-D-Arg-Phe-Lys-NH2) was used to demonstrate the role of Met(80)-Fe ligation in ischemia. Mitochondria were isolated from ischemicrat kidneys to determine sites of respiratory inhibition. Mitochondrial cyt c and cyt c Met-O were quantified by western blot, and cristae architecture was examined by electron microscopy. RESULTS: Biochemical and structural studies showed that SS-20 selectively targets cardiolipin (CL) and protects Met(80)-Fe ligation in cyt c. Ischemic mitochondria showed 17-fold increase in Met-O cyt c, and dramatic cristaeolysis. Loss of cyt c was associated with proteolytic degradation of OPA1. Ischemia significantly inhibited ET initiated by direct reduction of cyt c and coupled respiration. All changes were prevented by SS-20. CONCLUSION: Our results show that ischemia disrupts the Met(80)-Fe ligation of cyt c resulting in the formation of a globin-like pentacoordinated hemeFe(2+) that inhibits ET, and converts cyt c into an oxygenase to cause CL peroxidation and proteolytic degradation of OPA1, resulting in cyt c release. GENERAL SIGNIFICANCE: Cyt c heme structure represents a novel target for minimizing ischemic injury. SS-20, which we show to selectively target CL and protect the Met(80)-Fe ligation, minimizes ischemic injury and promotes ATP recovery.
Authors: Yu A Vladimirov; E V Proskurnina; D Yu Izmailov; A A Novikov; A V Brusnichkin; A N Osipov; V E Kagan Journal: Biochemistry (Mosc) Date: 2006-09 Impact factor: 2.487
Authors: Liana V Basova; Igor V Kurnikov; Lei Wang; Vladimir B Ritov; Natalia A Belikova; Irina I Vlasova; Andy A Pacheco; Daniel E Winnica; Jim Peterson; Hülya Bayir; David H Waldeck; Valerian E Kagan Journal: Biochemistry Date: 2007-02-24 Impact factor: 3.162
Authors: Christian Frezza; Sara Cipolat; Olga Martins de Brito; Massimo Micaroni; Galina V Beznoussenko; Tomasz Rudka; Davide Bartoli; Roman S Polishuck; Nika N Danial; Bart De Strooper; Luca Scorrano Journal: Cell Date: 2006-07-14 Impact factor: 41.582
Authors: Wangde Dai; Elissa Cheung; Rick J Alleman; Justin B Perry; Mitchell E Allen; David A Brown; Robert A Kloner Journal: Cardiovasc Drugs Ther Date: 2016-12 Impact factor: 3.727
Authors: Lena R Bartell; Lisa A Fortier; Lawrence J Bonassar; Hazel H Szeto; Itai Cohen; Michelle L Delco Journal: J Orthop Res Date: 2019-12-25 Impact factor: 3.494
Authors: Hazel H Szeto; Shaoyi Liu; Yi Soong; Surya V Seshan; Leona Cohen-Gould; Viacheslav Manichev; Leonard C Feldman; Torgny Gustafsson Journal: J Am Soc Nephrol Date: 2016-11-23 Impact factor: 10.121
Authors: Michelle L Delco; Edward D Bonnevie; Hazel S Szeto; Lawrence J Bonassar; Lisa A Fortier Journal: J Orthop Res Date: 2018-02-22 Impact factor: 3.494
Authors: Li-Hong Zhang; Xiang-Yang Zhu; Alfonso Eirin; Arash Aghajani Nargesi; John R Woollard; Adrian Santelli; In O Sun; Stephen C Textor; Lilach O Lerman Journal: Am J Physiol Renal Physiol Date: 2019-05-01
Authors: Gabriella MacDougall; Ryan S Anderton; Adam B Edwards; Neville W Knuckey; Bruno P Meloni Journal: J Mol Neurosci Date: 2016-11-20 Impact factor: 3.444
Authors: Gabriella MacDougall; Ryan S Anderton; Eden Ouliel; Junjie Gao; Sharon L Redmond; Neville W Knuckey; Bruno P Meloni Journal: Mol Cell Biochem Date: 2019-11-02 Impact factor: 3.396